A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

BACKGROUND: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Br J Cancer
मुख्य लेखकों: Lim, Bora, Murthy, Rashmi K., Lee, Jangsoon, Jackson, Summer A., Iwase, Toshiaki, Davis, Darren W., Willey, Jie S., Wu, Jimin, Shen, Yu, Tripathy, Debu, Alvarez, Ricardo, Ibrahim, Nuhad K., Brewster, Abenaa M., Barcenas, Carlos H., Brown, Powel H., Giordano, Sharon H., Moulder, Stacy L., Booser, Daniel J., Moscow, Jeffrey A., Piekarz, Richard, Valero, Vicente, Ueno, Naoto T.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738035/
https://ncbi.nlm.nih.gov/pubmed/31097774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0473-y
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन